How a specific bacterium affects fat and metabolism
Official title: Regulation of metabolic diseases by Clostridium immunis
Funded at Duke University · NIH-11091384 · Data updated 2026-11-12
This study is looking at a new type of bacteria called Clostridium immunis to see how it might help manage body fat and improve conditions like type 2 diabetes, which could lead to new treatment options for people dealing with these metabolic issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 25, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $241,500 |
| NIH project number | 1R56DK140174-01 |
| Project ID | NIH-11091384 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults experiencing abdominal obesity or metabolic syndrome.
✕Less likely to help
Patients with metabolic disorders unrelated to visceral fat accumulation may not benefit from this research.
What this research studies
This research investigates the role of Clostridium immunis, a newly identified bacterium, in regulating visceral adipose tissue (VAT) and its impact on metabolic diseases like type 2 diabetes. The study aims to understand the mechanisms by which this bacterium and its secreted substances can reduce body weight and triglycerides. By examining immune responses and energy expenditure, the research seeks to uncover how this bacterium can potentially alter fat accumulation in the body. Patients may benefit from insights into new treatments targeting metabolic disorders.
Why it matters
Potential benefit: If successful, this research could lead to novel therapeutic strategies for managing obesity and type 2 diabetes.
How similar studies have gone: Previous research has shown promise in using gut microbiota to influence metabolic health, suggesting potential for success in this novel approach.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Surana, Neeraj K — Duke University
- Study coordinator: Surana, Neeraj K
Related research
Other NIH-funded projects on the same topics.
-
Postnatal and Prenatal Base Editing Therapies for Metabolic Diseases
This grant aims to advance genetic medicine that could one day treat metabolic diseases before or after birth using precise genome editing techniques.
-
Postnatal and Prenatal Base Editing for Metabolic Diseases
A large NIH grant is funding research to develop gene-editing methods that could treat metabolic diseases before and after birth.
-
GLP-1 producing engineered probiotics to help manage metabolic diseases
A research project aims to create probiotic bacteria that constantly deliver GLP-1 to help people with type 2 diabetes and obesity manage their condition.
-
Changing bile acids to help diabetes, fatty liver, and weight problems
This project is developing medicines that shift bile acid balance in the liver to help adults with type 2 diabetes, fatty liver disease, or obesity.
-
Precise gene editing before or after birth for metabolic diseases
This project develops precise gene-editing treatments given before birth or soon after to correct genetic metabolic conditions in children.
-
Understanding the links between heart, kidney, and metabolic diseases
This study is looking at how obesity and diabetes can lead to heart and kidney problems, especially for people in Mississippi, and it aims to find new ways to help improve health for those dealing with these issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.